Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

Background Inhibitors of immune checkpoint programmed cell death protein 1 (PD-1) receptor on T cells have shown remarkable clinical outcomes in metastatic melanoma. However, most patients are resistant to therapy. Production of extracellular adenosine, via CD73-mediated catabolism of AMP, contribut...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Dirk Schadendorf, Celeste Lebbe, Teresa Amaral, Benjamin Weide, Mariaelena Capone, Gabriele Madonna, Lucia Festino, Reinhard Dummer, Domenico Mallardo, Paolo A Ascierto, Piotr Rutkowski, Jason John Luke, Kilian Wistuba-Hamprecht, Mitchell P Levesque, Roberta Turiello, Elva Morretta, Maria Chiara Monti, Rosa Azzaro, Laurence Imhof, Marc Chevrier, Antje Sucker, Aldo Pinto, Silvana Morello
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMJ Publishing Group 2020-10-01
Serier:	Journal for ImmunoTherapy of Cancer
Online adgang:	https://jitc.bmj.com/content/8/2/e001689.full
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!